Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Equities research analysts at Roth Capital issued their Q2 2024 EPS estimates for Cardiol Therapeutics in a research note issued to investors on Wednesday, June 26th. Roth Capital analyst J. Wittes anticipates that the company will post earnings per share of ($0.09) for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04).
Read Our Latest Research Report on CRDL
Cardiol Therapeutics Trading Up 1.0 %
Shares of NASDAQ:CRDL opened at $2.02 on Friday. Cardiol Therapeutics has a 52-week low of $0.66 and a 52-week high of $3.12. The stock has a market capitalization of $139.38 million, a price-to-earnings ratio of -5.77 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.81 and a current ratio of 2.81. The stock’s 50-day simple moving average is $2.21 and its two-hundred day simple moving average is $1.65.
Institutional Trading of Cardiol Therapeutics
A hedge fund recently raised its stake in Cardiol Therapeutics stock. Laird Norton Trust Company LLC boosted its holdings in Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) by 63.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 100,000 shares of the company’s stock after buying an additional 38,673 shares during the period. Laird Norton Trust Company LLC owned 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.49% of the company’s stock.
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Articles
- Five stocks we like better than Cardiol Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- 3 Warren Buffett Stocks to Buy Now
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.